<sup>18</sup>F-FDG PET/CT在乳腺癌术后随访中的价值

张亶; 章斌; 邓胜明; 吴翼伟; 张亶; 章斌; 邓胜明; 吴翼伟

doi:10.3760/cma.j.issn.1673-4114.2017.03.001

[1]

Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer incidence in China for 2000 and projections for 2005[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(1):243-250.

[2]

Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer[J]. Hematol Oncol Clin North Am, 2007, 21(2):257-272. DOI:10. 1016/j.hoc.2007.03.001.

[3]

Berman AT, Thukral AD, Hwang WT, et al. Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment[J]. Clin Breast Cancer, 2013, 13(2):88-94. DOI:10.1016/j.clbc.2012.11.001.

[4]

Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer:hightlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol, 2013, 24(9):2206-2223. DOI:10.1093/annonc/mdt303.

[5]

Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11):783-792. DOI:10.1056/NEJM200103153441101.

[6]

Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer[J]. J Clin Oncol, 2010, 28(7):1124-1130. DOI:10.1200/JCO. 2008.21.4437.

[7]

Mavi A, Cermik TF, Urhan M, et al. The effects of estrogen, progesterone, and C-erbB-2 receptor states on ¹⁸F-FDG uptake of primary breast cancer lesions[J]. J Nucl Med, 2007, 48(8):1266-1272. DOI:10.2967/jnumed.106.037440.

[8]

陈道宝, 杨红健. 乳腺癌ER与FES-PET[J]. 中国肿瘤, 2008, 17(7):588-592. DOI:10.3969/j.issn.1004-0242.2008.07.013.
Chen DB, Yang HJ. Estrogen receptor and fluoroestradiol-positron emission tomography in breast cancer[J]. Chin Cancer, 2008, 17(7):588-592. doi: 10.3969/j.issn.1004-0242.2008.07.013

[9]

Montagna E, Bagnardi V, Rotmensz N, et al. Breast cancer subtypes and outcome after local and regional relapse[J]. Ann Oncol, 2012, 23(2):324-331. DOI:10.1093/annonc/mdr129.

[10]

Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2(HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors[J]. J Chin Oncol, 2012, 30(6):593-599. DOI:10.1200/JCO.2010.33.8889.

[11]

Zangheri B, Messa C, Picchio M, et al. PET/CT and breast cancer[J]. Eur J Nucl Med Mol Imaging, 2004, 31 supple1:S135-142. DOI:10.1007/s00259-004-1536-7.

[12]

Cermik TF, Mavi A, Basu S, et al. Impact of FDG PET on the pre-operative staging of newly diagnosed breast cancer[J]. Eur J Nucl Med Mol Imaging, 2008, 35(3):475-483. DOI:10.1007/s00259-007-0580-5.

[13]

陈建伟, 王杰, 刘标, 等. PET/CT与胸部诊断CT在乳腺癌术后随访中的比较[J]. 南京医科大学学报:自然科学版, 2010, 30(2):195-198, 213.
Chen JW, Wang J, Liu B, et al. Impact of ¹⁸F-FDG PET/CT compared with diagnostic CT on following-up breast cancer after surgery[J]. Acta Univ Med Nanjing(Natural Science), 2010, 30(2):195-198, 213.

[14]

Murakami R, Kumita S, Yoshida T, et al. FDG-PET/CT in the diag-nosis of recurrent breast cancer[J]. Acta Radiol, 2012, 53(1):12-16. DOI:10.1258/ar.2011.110245.

[15]

刘晓强, 周海中, 杜鹃. 乳腺癌患者术前¹⁸F-FDG PET/CT显像肿瘤代谢体积测定的预后价值[J]. 实用临床医药杂志, 2014, 18(21):55-59. DOI:10.7619/jcmp.201421016.
Liu XQ, Zhou HZ, Du J. Prognositc value of metabolic tumor volume measured by ¹⁸F-FDG PET/CT imaging in preoperative breast cancer patients[J]. J Clin Med Prac, 2014, 18(21):55-59. doi: 10.7619/jcmp.201421016

[16]

Maffione AM, Lopci E, Bluemel C, et al. Diagnostic accuracy and impact on management of ¹⁸F-FDG PET and PET/CT in colorectal liver metastasis:a meta-analysis and systematic review[J]. Eur J Nucl Med Mol Imaging, 2015, 42(1):152-163. DOI:10.1007/s00259-014-2930-4.